(THE NEW AMERICAN) – The pharmaceutical company Moderna announced it is set to request an emergency use authorization (EUA) from the Food and Drug Administration (FDA) for its Covid shot for children ages six months to six years old. The vaccine’s efficacy is estimated to be less than 44 percent for infants, and less than 38 percent for children aged two to six.
According to the announcement posted on Moderna’s website, Phase 2/3 of the so-called KidCOVE study showed “a robust neutralizing antibody response” and “a favorable safety profile” of the two-shot dose that contained a quarter, or 25 μg, of the adult mRNA dose.
KidCOVE tested Moderna’s shot on children in two age groups: from six months to under two years, and from two years to under six years of age.
The post Moderna wants COVID shots for infants appeared first on WND.
